

## **Engagement Report for Clinical Commissioning Policies**

Unique Reference Number	1713	
Policy Title	Anakinra for periodic fevers and autoinflammatory disease	
Lead Commissioner	Joan Ward	
Clinical Reference Group	Allergy and Immunology	
Which stakeholders were contacted to be involved in policy development?	Allergy and Immunology CRG and registered stakeholders Specialised Rheumatology CRG and registered stakeholders Adult Rheumatology CRG and registered stakeholders Dermatology CRG and registered stakeholders list Paediatric Medicine CRG and registered stakeholders list Specialised Pain CRG and registered stakeholders British Association for Immunology; bsi@immunology.org; BPAIIG (British Paediatric Allergy ,Immunity and Infection Group; BSPAR- British society of paediatric and adolescent rheumatology for RCPCH Royal College of Pathologists; Royal College of Physicians; British Association of Dermatologists Rare Autoinflammatory group UK;	
Identify the relevant Royal College or Professional Society to the policy and indicate how they have been involved	British Association for Immunology; bsi@immunology.org; BPAIIG (British Paediatric Allergy ,Immunity and Infection Group; BSPAR- British society of paediatric and adolescent rheumatology for RCPCH Royal College of Pathologists; Royal College of Physicians; British Association of Dermatologists These organisations were emailed and asked to comment	
Which stakeholders	Rare Autoinflammatory Conditions Community- UK (RACC- UK) Clinician GSST	

have actually been involved?	PPV rep
Explain reason if there is any difference from previous question	Clinical Reference Group (Paediatric Medicine)
Identify any particular stakeholder organisations that may be key to the policy development that you have approached that have yet to be engaged. Indicate why?	
How have stakeholders been involved? What engagement methods have been used?	Stakeholders were emailed and asked to comment
What has happened or changed as a result of their input?	<ol> <li>The language in the policy has been amended to be more inclusive in relation to gender</li> <li>The dosing in relation to children has been clarified</li> </ol>
How are stakeholders being kept informed of progress with policy development as a result of their input?	Following the approval of the Programme Board, stakeholders will be emailed the response of the PWG.
What level of wider public consultation is recommended by the CRG for the NPOC Board to agree	Up to 6 weeks

as a result of	
stakeholder	
involvement?	

